Tendinous Xanthoma - Causes, Treatment & When to See a Doctor

```html

What is Tendinous Xanthoma?

Tendinous xanthoma (also called tendon xanthoma) is a benign, yellow‑orange deposit of cholesterol‑rich material that forms within tendons, most commonly the Achilles tendon, extensor tendons of the hands, and the patellar tendon. These nodules feel firm or rubbery and can be visible under the skin. Tendinous xanthomas are not primary skin lesions; they arise from the accumulation of lipid‑laden macrophages (foam cells) within the connective tissue of the tendon.

Although they are harmless in themselves, tendinous xanthomas are an important clinical clue because they almost always signal an underlying disorder of lipid metabolism—particularly familial hypercholesterolemia (FH). Detecting them early can lead to timely treatment that reduces the risk of premature cardiovascular disease.

Common Causes

The majority of tendinous xanthomas are linked to inherited or acquired disorders that cause markedly high low‑density lipoprotein (LDL) cholesterol. Below are the most frequent conditions associated with these lesions:

• Familial hypercholesterolemia (FH) – heterozygous (most common cause; prevalence ≈ 1 in 250).
• Familial hypercholesterolemia – homozygous (rare, severe; presents in childhood).
• Familial combined hyperlipidemia – elevated LDL and/or triglycerides.
• Familial dysbetalipoproteinemia (Type III hyperlipoproteinemia) – defective ApoE.
• Sitosterolemia (phytosterolemia) – accumulation of plant sterols.
• Secondary hypercholesterolemia due to nephrotic syndrome – loss of proteins in urine raises hepatic LDL synthesis.
• Hypothyroidism – reduced LDL receptor activity leading to high LDL.
• Cholesterol‑lowering medication discontinuation or poor adherence – can precipitate rapid LDL rise.
• Metabolic syndrome with severe hypertriglyceridemia (rarely produces tendon xanthomas, but can coexist).
• Rare genetic disorders affecting LDL‑receptor trafficking (e.g., ARH mutations).

In the vast majority of cases, FH (especially the heterozygous form) is the culprit, accounting for >90 % of tendinous xanthoma presentations.

Associated Symptoms

Because the nodules develop within tendons, patients may notice the following alongside the visible or palpable lesions:

• Feeling of tightness or “thickening” of the affected tendon.
• Occasional mild pain or discomfort, especially after prolonged activity.
• Reduced range of motion in the nearby joint (e.g., limited ankle dorsiflexion with Achilles involvement).
• Family members with similar skin or tendon lesions.
• Signs of systemic hyperlipidemia:
  • Premature coronary artery disease (angina, heart attack before age 55 in men, 65 in women).
  • Arcus cornealis (white ring around the cornea).
  • Other types of xanthomas (tuberous, eruptive, plane).

When to See a Doctor

Seek medical evaluation promptly if you notice any of the following:

• Firm, yellow‑orange nodules on the Achilles tendon, hands, feet, or knees.
• A family history of early‑onset heart disease or known high cholesterol.
• New or worsening pain in the tendon that interferes with daily activities.
• Chest pain, shortness of breath, or unexplained fatigue—possible heart‑related complications.
• Sudden swelling or redness over a tendon nodule (could indicate infection or inflammation).

Because tendinous xanthomas signal a high risk for cardiovascular events, early assessment can be life‑saving.

Diagnosis

Diagnosing tendinous xanthoma involves a combination of clinical examination, imaging, and laboratory testing.

1. Clinical Examination

• Visual inspection for yellow‑orange plaques.
• Palpation to assess consistency (firm, non‑compressible) and size.
• Assessment of tendon function and range of motion.

2. Laboratory Studies

• Lipid profile – total cholesterol, LDL‑C, HDL‑C, triglycerides.
• Genetic testing for mutations in LDLR, APOB, PCSK9, or other FH‑related genes (especially if FH is suspected).
• Thyroid‑stimulating hormone (TSH) to rule out hypothyroidism.
• Urinalysis for proteinuria if nephrotic syndrome is a concern.

3. Imaging

• Ultrasound – readily shows hyperechoic (bright) masses within the tendon and can measure thickness.
• Magnetic resonance imaging (MRI) – provides detailed anatomy, especially useful before surgery.
• Computed tomography (CT) or X‑ray – can demonstrate calcified xanthomas, though less sensitive.

4. Histopathology (Rare)

A biopsy is rarely needed but, when performed, shows collections of lipid‑laden foam cells, cholesterol clefts, and a fibrous capsule.

Treatment Options

Management focuses on two goals: (1) lowering the systemic lipid burden to prevent new xanthomas and cardiovascular disease, and (2) addressing existing tendon lesions if they cause functional problems.

1. Lipid‑Lowering Therapy

• Statins (e.g., atorvastatin, rosuvastatin) – first‑line; reduce LDL‑C by 30‑50 %.
• Ezetimibe – added when statins alone are insufficient.
• PCSK9 inhibitors (alirocumab, evolocumab) – for patients with FH who do not reach target LDL‑C on maximal statin‑ezetimibe therapy.
• Bile‑acid sequestrants (cholestyramine) – useful in some patients but may cause GI side effects.
• Lipoprotein apheresis – reserved for homozygous FH or severe heterozygous FH with refractory disease.

Guidelines from the American College of Cardiology/American Heart Association (ACC/AHA) recommend treating FH patients to achieve LDL‑C < 70 mg/dL (or < 55 mg/dL for very high‑risk individuals)【1】.

2. Lifestyle Modifications

• Adopt a heart‑healthy diet: high‑fiber, low‑saturated‑fat, limit trans fats, and incorporate plant sterols.
• Engage in regular aerobic activity (≥150 min/week of moderate intensity).
• Maintain a healthy weight; waist circumference < 40 in (men) or < 35 in (women).
• Avoid tobacco and limit alcohol (<2 drinks/day for men, <1 for women).

3. Direct Management of the Xanthoma

• Observation – many xanthomas shrink slowly once LDL is controlled; no intervention needed if asymptomatic.
• Surgical excision – considered for large, painful nodules that limit function, especially in the hand or Achilles tendon.
• Laser or cryotherapy – rarely used; more effective for superficial eruptive xanthomas rather than deep tendon lesions.
• Physical therapy – can improve tendon flexibility and reduce discomfort while lesions are being treated medically.

4. Monitoring

Patients should have lipid panels checked every 3–6 months after initiating therapy, and annually thereafter once stable. Tendon thickness can be re‑evaluated with ultrasound to track lesion regression.

Prevention Tips

While you cannot change genetics, you can dramatically lower the risk of developing new tendinous xanthomas and the cardiovascular complications they herald.

• Screen family members early if a relative has FH or tendon xanthomas; cascade testing is endorsed by the CDC and NHLBI.
• Start statin therapy early in confirmed FH (often by age 8–10 in homozygous, early teens in heterozygous).
• Maintain LDL‑C at guideline‑recommended levels throughout life.
• Adopt a Mediterranean‑style diet rich in olive oil, nuts, fish, fruits, and vegetables.
• Stay active – regular exercise improves HDL‑C and helps lower LDL‑C.
• Avoid smoking and second‑hand smoke exposure.
• Keep routine follow‑up appointments; never stop medication without discussing it with your clinician.

Emergency Warning Signs

Key Take‑aways

Tendinous xanthomas are visible markers of underlying lipid disorders, most commonly familial hypercholesterolemia. Early recognition, aggressive lipid‑lowering therapy, and lifestyle changes can halt the growth of existing lesions and dramatically reduce the risk of premature heart disease. Regular medical follow‑up, family screening, and awareness of emergency symptoms are essential for optimal outcomes.

---

References:

1. American College of Cardiology/American Heart Association. 2022 Guideline on the Management of Blood Cholesterol. JACC. 2022;79(19):e353‑e430.
2. Mayo Clinic. Tendon xanthoma. Accessed May 2026. https://www.mayoclinic.org/diseases-conditions/tendon-xanthoma
3. National Lipid Association. Familial Hypercholesterolemia: Clinical Guidance. 2023.
4. World Health Organization. WHO Guideline on Familial Hypercholesterolemia. 2023.
5. Cleveland Clinic. Xanthomas: What They Mean and How to Treat Them. 2024.

```